News
HSTO
0.213
0.00%
0.000
Weekly Report: what happened at HSTO last week (1028-1101)?
Weekly Report · 3d ago
Weekly Report: what happened at HSTO last week (1021-1025)?
Weekly Report · 10/28 11:40
Weekly Report: what happened at HSTO last week (1014-1018)?
Weekly Report · 10/21 11:35
Weekly Report: what happened at HSTO last week (1007-1011)?
Weekly Report · 10/14 12:09
Weekly Report: what happened at HSTO last week (0930-1004)?
Weekly Report · 10/07 11:56
Weekly Report: what happened at HSTO last week (0923-0927)?
Weekly Report · 09/30 11:48
Weekly Report: what happened at HSTO last week (0916-0920)?
Weekly Report · 09/23 11:47
Weekly Report: what happened at HSTO last week (0909-0913)?
Weekly Report · 09/16 11:35
Weekly Report: what happened at HSTO last week (0902-0906)?
Weekly Report · 09/09 11:48
Weekly Report: what happened at HSTO last week (0826-0830)?
Weekly Report · 09/02 11:52
Weekly Report: what happened at HSTO last week (0819-0823)?
Weekly Report · 08/26 11:49
Weekly Report: what happened at HSTO last week (0812-0816)?
Weekly Report · 08/19 11:33
Weekly Report: what happened at HSTO last week (0805-0809)?
Weekly Report · 08/12 11:36
Weekly Report: what happened at HSTO last week (0729-0802)?
Weekly Report · 08/05 11:48
Weekly Report: what happened at HSTO last week (0722-0726)?
Weekly Report · 07/29 11:36
Weekly Report: what happened at HSTO last week (0715-0719)?
Weekly Report · 07/22 11:37
Weekly Report: what happened at HSTO last week (0708-0712)?
Weekly Report · 07/15 11:33
Weekly Report: what happened at HSTO last week (0701-0705)?
Weekly Report · 07/08 11:35
Weekly Report: what happened at HSTO last week (0624-0628)?
Weekly Report · 07/01 11:36
Weekly Report: what happened at HSTO last week (0617-0621)?
Weekly Report · 06/24 11:44
More
Webull provides a variety of real-time HSTO stock news. You can receive the latest news about Histogen Inc through multiple platforms. This information may help you make smarter investment decisions.
About HSTO
Histogen Inc. is a clinical-stage therapeutics company. The Company is focused on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function. Its product candidates include emricasan, CTS-2090 and CTS-2096. It develops emricasan for acute bacterial skin and skin structure infections (ABSSSI) as well evaluating its use for other infectious diseases. Its pipeline also includes novel preclinical product candidates including CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of certain inflammatory diseases. Emricasan is an orally available pan-caspase inhibitor designed to reduce the activities of human caspases, which are enzymes that mediate inflammation and apoptosis. CTS-2090 and CTS-2096 are selective caspase-1 inhibitors targeting inflammasome activation and to treat a variety of inflammation mediated diseases.